MET and renal cell carcinoma: In RCC, many studies have suggested that c-Met expression is associated with significantly inferior clinicopathological features, such as tumor grade [27, 28–31, 36, 38], primary tumor stage [30, 31, 36], lymphatic invasion [27], metastases [30, 35, 38], and worse progression-free survival [37] or OS [31, 34, 36].